Peptide Straight Talk · Educational flash (between numbered issues)
Peptide Straight Talk editorial desk
Between numbered issues. Registry watch — not medical advice.
Taxonomy: REG = ClinicalTrials.gov registry record (design/status ≠ posted results ≠ proven therapy) · REG-AUTH = regulatory / authority statement (not a therapy green light)
What people are saying
Recent social posts about the Arkansas listing — NCT07803250, a University of Arkansas / University of Arkansas for Medical Sciences (UAMS) Phase 1 rotator-cuff study — have drawn attention to Body Protection Compound-157 (BPC-157) as a human recovery question. Soft-tissue interest is high; formal human evidence has stayed limited. A U.S. university REG row on ClinicalTrials.gov has drawn public attention.
What’s actually at stake
A U.S. registry listing matters because it is a public record you can re-check — sponsor, status, phase, estimated dates, endpoints — rather than an unverified protocol claim circulating without a registry page. What appears on ClinicalTrials.gov today includes a U.S. Phase 1 listing and a separate Phase 2 study abroad listed as recruiting. Tracking those listings does not mean treating a registry row as settled therapy or automatic authorization.
Why people are excited
What’s driving the interest:
A U.S. university Phase 1 REG on rotator-cuff recovery. Arkansas / UAMS listing NCT07803250 puts a formal human protocol on ClinicalTrials.gov that people can open and re-check.
A separate recruiting Phase 2 design abroad. NCT07437547 (Shenzhen / Hudson Biotech) lists a hamstring study with return-to-sport and MRI endpoints alongside standardized rehab.
Compounding discussion at FDA. Pharmacy Compounding Advisory Committee (PCAC) voted to recommend BPC-157-related bulk substances for the 503A Bulks List — often read as progress on access rules, even though that recommendation is not itself a Bulks List change or drug approval (deeper dive in Issue #2).
A long preclinical backlog. Years of animal soft-tissue and vascular signals (reviewed elsewhere) sit behind the desire to see human protocols on the calendar.
What the registry + compounding record actually says
NCT07803250 (Arkansas / UAMS) — REG
As of September 27, 2026, ClinicalTrials.gov lists:
Field | Record |
|---|---|
Title | Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery |
Status | NOT_YET_RECRUITING |
Phase | PHASE1 pilot framing on the record |
Sponsor / site | University of Arkansas; UAMS Medical Center, Little Rock, Arkansas, United States |
Design (as listed) | Interventional; randomized; parallel; quadruple masking; record summary also describes randomized, double-blind, placebo-controlled |
Enrollment | 30 estimated; brief summary says Twenty patients |
Primary endpoint (listed) | Shoulder strength (isometric abduction / external rotation) at baseline, 12 weeks, and 5 months post-op |
Start | 2027-01-01 (estimated) |
Primary / study completion | 2027-08-01 (estimated) |
First posted | September 3, 2026 |
Last posted update | September 3, 2026 |
Results | No results posted (`hasResults` false) |
The registry also conflicts on the comparator in quoted phrases. The brief summary describes a “randomized, double-blind, placebo-controlled” pilot and says participants will receive “BPC-157 or a saline placebo.” The Sham arm description says participants “will receive normal saline.” Separately, the Sham (No Treatment) intervention wording says participants “will not receive any active treatment or placebo injections.” The intended comparator therefore needs clarification. Phase 1 can be randomized; a circulating “first U.S. injectable BPC RCT” claim remains unverified rather than disproven by phase alone. Estimated dates are not locked calendars. The registry provides no confirmed results-release date.
NCT07437547 (Shenzhen / Hudson Biotech) — REG
As of September 27, 2026, ClinicalTrials.gov lists:
Field | Record |
|---|---|
Title / acronym | BPC 157 for Acute Hamstring Muscle Strain Repair (BPC-HAMSTR) |
Status | RECRUITING (the record lists recruiting) |
Phase | PHASE2 |
Sponsor / site | Hudson Biotech; Peking University Shenzhen Hospital (China) |
Design | Randomized 1:1; quadruple masking; investigational BPC-157 or placebo plus standardized rehab; magnetic resonance imaging (MRI)–confirmed grade II hamstring strain |
Enrollment | 120 estimated |
Start | 2026-02-02 (actual) |
Primary completion | 2027-02-14 (estimated) |
Study completion | 2028-02-17 (estimated) |
Co-primary endpoints | Time to return to unrestricted sport; change in MRI-assessed injury volume at Day 14 |
First posted | February 27, 2026 |
Last posted update | February 27, 2026 |
Results | No results posted (`hasResults` false) |
The record lists recruiting; its last posted update was February 27, 2026. We have not independently confirmed current enrollment activity. Enrollment remains 120 estimated, not a claim that 120 participants are enrolled. This is a separate Phase 2 listing alongside the Arkansas study.
Advisory recommendation ≠ Bulks List change or drug approval (REG-AUTH)
PCAC voted to recommend BPC-157-related bulk substances for the 503A Bulks List (as reported by Reuters). That recommendation is not itself a Bulks List change or drug approval — FDA retains the final decision. We’ll go deeper on the FDA / compounding record in Issue #2; this flash does not deep-dive it.
BPC-157 is not an FDA-approved drug for the soft-tissue uses people discuss. FDA’s bulk compounding safety-risks framing for certain routes preserves uncertainty language (immunogenicity / impurity / API-characterization concerns; agency lacks sufficient information to know whether the drug would cause harm in humans) — REG-AUTH, not “harm is proven,” and not “legalized.”
What remains open — and what we’ll watch
Arkansas is listed as not yet recruiting; social attention is not enrollment.
Enrollment conflict and comparator wording on NCT07803250 remain unresolved.
No confirmed results-release date on either record (Arkansas estimated completion August 1, 2027; Shenzhen study completion 2028-02-17 estimated — study-completion fields, not results dates).
Both NCTs: `hasResults` false.
Preclinical soft-tissue signals help explain interest; they are not human efficacy or safety outcomes.
We’ll update this flash if either NCT’s status, internal inconsistencies, enrollment figures, or results posting moves.
Next newsletter: Our next numbered issue — Issue #2 — will be a deeper dive on BPC-157 (claims vs. the science record, including the FDA / compounding record). This flash is only the Arkansas heat / registry-watch piece.
Sources (primary)
REG — NCT07803250 (Arkansas / UAMS rotator cuff): https://clinicaltrials.gov/study/NCT07803250
REG — NCT07437547 (BPC-HAMSTR; Shenzhen / Hudson Biotech Phase 2): https://clinicaltrials.gov/study/NCT07437547
REG-AUTH — FDA, July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
REG-AUTH — FDA, Advisory Committees Give FDA Critical Advice and the Public a Voice (nonbinding recommendations; FDA retains final decisions): https://www.fda.gov/consumers/consumer-updates/advisory-committees-give-fda-critical-advice-and-public-voice
REG-AUTH — FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Secondary (reporting) — Reuters, FDA advisers back first four of seven unapproved peptides under review for looser rules (July 23, 2026): https://www.reuters.com/legal/litigation/us-fda-advisers-weigh-restrictions-seven-peptides-industry-presses-expansion-2026-07-23/
Registry check: September 27, 2026. Re-check both NCT statuses before any publish.
Educational / research framing only. Not medical advice. Not a recommendation to use, compound, buy, or sell any product. No dosing, sourcing, or “you should take this.” Re-check ClinicalTrials.gov before treating status as current.
